DOI:
10.1055/s-00000097
Deutsche Zeitschrift für Onkologie
LinksClose Window
References
Escudier B, Koralewski P, Pluzanska A, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Moore N. investigators. obotA.
A randomized, controlled, double-blind phase III study
(AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon- a2a as first-line
therapy in metastatic renal cell carcinoma.
J Clin Oncol 2007; 25
We do not assume any responsibility for the contents of the web pages of other providers.